MapLight Therapeutics was assigned a Hold rating ahead of its Phase 2 ZEPHYR readout for ML-007C-MA in schizophrenia expected ...

The study cited in rumors about the negative effects of sunscreen did not actually draw the conclusion shared by some people ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

Good results reported with emergency-use and compassionate-use cases ...

Valion Bio, Inc. (Nasdaq: VBIO) ("Valion Bio" or the "Company") today announced that the Armed Forces Radiobiology Research Institute ("AFRRI"), a division of the U.S. Department of War ("DoW"), in ...

Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by mitochondrial dysfunction and insulin resistance, today announced enrollment and dosing has ...

The question is not how clinicians can be made more resilient. It is why an institution performing at the highest level of ...

Lundbeck to present new Vyepti and bocunebart migraine portfolio data in EAN Congress, 2026: Valby, Denmark Thursday, June 25, 2026, 17:00 Hrs [IST] Lundbeck, a biopharma company ...

THE ANNUAL world-leading course in interventional cardiology, EuroPCR, welcomed 12,147 participants to Paris, France, for a dynamic ...

Lundbeck to present new data of eptinezumab and bocunebart EAN Congress 2026 on June 27-30 in Geneva: Valby, Denmark Friday, June 26, 2026, 13:00 Hrs [IST] H. Lundbeck A/S (Lundbe ...

Apnimed, Inc., a late-stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related ...

Sjögren’s disease (SjD) is a chronic, multisystem autoimmune disorder characterised by lymphocytic infiltration of exocrine ...